JP2024502231A - Nav1.8電位依存性ナトリウムチャネルを阻害するためおよびNav1.8介在疾患を治療するために有用な化学化合物 - Google Patents

Nav1.8電位依存性ナトリウムチャネルを阻害するためおよびNav1.8介在疾患を治療するために有用な化学化合物 Download PDF

Info

Publication number
JP2024502231A
JP2024502231A JP2023536951A JP2023536951A JP2024502231A JP 2024502231 A JP2024502231 A JP 2024502231A JP 2023536951 A JP2023536951 A JP 2023536951A JP 2023536951 A JP2023536951 A JP 2023536951A JP 2024502231 A JP2024502231 A JP 2024502231A
Authority
JP
Japan
Prior art keywords
pain
compound
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023536951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502231A5 (https=
Inventor
グアン、ジー
デイビッド、グレン、ウォッシュバーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2024502231A publication Critical patent/JP2024502231A/ja
Publication of JP2024502231A5 publication Critical patent/JP2024502231A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023536951A 2020-12-18 2021-12-16 Nav1.8電位依存性ナトリウムチャネルを阻害するためおよびNav1.8介在疾患を治療するために有用な化学化合物 Ceased JP2024502231A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063127341P 2020-12-18 2020-12-18
US63/127,341 2020-12-18
PCT/EP2021/086101 WO2022129283A1 (en) 2020-12-18 2021-12-16 Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases

Publications (2)

Publication Number Publication Date
JP2024502231A true JP2024502231A (ja) 2024-01-18
JP2024502231A5 JP2024502231A5 (https=) 2024-12-20

Family

ID=79025144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536951A Ceased JP2024502231A (ja) 2020-12-18 2021-12-16 Nav1.8電位依存性ナトリウムチャネルを阻害するためおよびNav1.8介在疾患を治療するために有用な化学化合物

Country Status (13)

Country Link
EP (1) EP4262978A1 (https=)
JP (1) JP2024502231A (https=)
KR (1) KR20230121827A (https=)
CN (1) CN116710463A (https=)
AU (1) AU2021403606B2 (https=)
CA (1) CA3202328A1 (https=)
CL (1) CL2023001750A1 (https=)
CO (1) CO2023008049A2 (https=)
IL (1) IL303795A (https=)
MX (1) MX2023007244A (https=)
PH (1) PH12023551406A1 (https=)
SA (1) SA523441263B1 (https=)
WO (1) WO2022129283A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500335A (ja) * 2013-12-19 2017-01-05 アルマック・ディスカバリー・リミテッドAlmac Discovery Limited Wee−1キナーゼ阻害剤として有用なピリミドピリミジノン
JP2020519661A (ja) * 2017-05-16 2020-07-02 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated ナトリウムチャネルの調節因子としての重水素化ピリドンアミドおよびそのプロドラッグ
WO2020261114A1 (en) * 2019-06-27 2020-12-30 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as nav1.8 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2931550C (en) * 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500335A (ja) * 2013-12-19 2017-01-05 アルマック・ディスカバリー・リミテッドAlmac Discovery Limited Wee−1キナーゼ阻害剤として有用なピリミドピリミジノン
JP2020519661A (ja) * 2017-05-16 2020-07-02 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated ナトリウムチャネルの調節因子としての重水素化ピリドンアミドおよびそのプロドラッグ
WO2020261114A1 (en) * 2019-06-27 2020-12-30 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as nav1.8 inhibitors

Also Published As

Publication number Publication date
MX2023007244A (es) 2023-06-29
CL2023001750A1 (es) 2024-01-19
CO2023008049A2 (es) 2023-06-30
SA523441263B1 (ar) 2025-01-07
AU2021403606B2 (en) 2024-11-14
KR20230121827A (ko) 2023-08-21
PH12023551406A1 (en) 2024-01-22
IL303795A (en) 2023-08-01
AU2021403606A1 (en) 2023-06-22
WO2022129283A1 (en) 2022-06-23
EP4262978A1 (en) 2023-10-25
CN116710463A (zh) 2023-09-05
CA3202328A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
JP7701880B2 (ja) NaV1.8阻害剤としての2,3-ジヒドロキナゾリン化合物
JP7443495B2 (ja) ヘテロ環式rip1キナーゼ阻害剤
JP5795630B2 (ja) 抗癌及び抗増殖活性を示すシクロプロピルジカルボキサミド及び類似体
AU2021224733A1 (en) Pyridopyrimidine derivatives as KRAS inhibitors
JP2023554430A (ja) Nav1.8阻害剤としての含窒素2,3-ジヒドロキナゾリノン化合物
KR20220105425A (ko) 티아졸로피리딘 또는 이의 약학적으로 허용 가능한 염 및 이의 용도
JP2025522369A (ja) Nav1.8阻害剤としての縮合含窒素2,3-ジヒドロキナゾリノン化合物
CA3253274A1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECIPIENT
CA3204891A1 (en) Pyridine derivatives as modulators of sortilin activity
US20250084112A1 (en) Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases
JP2024502231A (ja) Nav1.8電位依存性ナトリウムチャネルを阻害するためおよびNav1.8介在疾患を治療するために有用な化学化合物
US20230416287A1 (en) Chemical Compounds
JP2009067762A (ja) 神経難病の画像診断薬
KR100267059B1 (ko) 3-비닐퀴놀린 유도체 및 약학적으로 허용되는 그의 염

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251029

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251128

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20260220